Skip to search formSkip to main content

TNP 351

Known as: TNP-351 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Alimta, as well as homo-Alimta, a nonbridged analogue of Alimta, and TNP-351 have been prepared by a new method that involves… Expand
Is this relevant?
2000
2000
The glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-g lutamic acid (1b, TNP-351… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
1997
1997
We have established an Adriamycin (ADM)-resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM 100, which shows… Expand
Is this relevant?
1996
1996
The glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid (1b, TNP-351… Expand
Is this relevant?
1995
1995
The clinical phase I study of TNP-351, an antifolate drug having a novel structure, was performed through a multicenter… Expand
Is this relevant?
1995
1995
Either the alpha- or gamma-carboxyl group of the glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5- yl… Expand
Is this relevant?
1994
1994
N-{4-[3-(2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl}-l-glutamic acid (TNP-351), characterized by a pyrrolo[2,3-d… Expand
  • figure 1
Is this relevant?
Review
1993
Review
1993
Two analogues of cytosine arabinoside (ara-C) and three analogues of methotrexate (MTX) are under their clinical studies in Japan… Expand
Is this relevant?